TAT-N15

TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke[1][2].

Product Specifications

CAS Number

2415370-74-8

UNSPSC

12352209

Target

Akt; Interleukin Related; NF-κB; STAT

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

O=C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCSC)C(N[C@@H](CCSC)C(N1[C@@H](CCC1)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N5[C@@H](CCC5)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC6=CC=C(C=C6)O)N

Molecular Formula

C155H250N48O40S3

Molecular Weight

3522.14

References & Citations

[1]Liu Y, et al. A novel p55PIK signaling peptide inhibitor alleviates neuroinflammation via the STAT3/NF-kB signaling pathway in experimental stroke[J]. Journal of Stroke and Cerebrovascular Diseases, 2024, 33 (7) : 107736.|[2]Wang T, et al. p55PIK deficiency and its NH2-terminal derivative inhibit inflammation and emphysema in COPD mouse model[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2021, 321 (1) : L159-L173.